This recombinant monoclonal antibody is a research-grade biosimilar to atenastobart, designed to target TNFRSF9 (tumor necrosis factor receptor superfamily member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and effector function. Upon binding with its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify cellular immune responses. This receptor has emerged as a significant target in immuno-oncology research due to its ability to promote anti-tumor immunity and enhance T cell-mediated cytotoxicity against malignant cells.
Atenastobart is an investigational agonistic antibody developed to stimulate TNFRSF9 signaling, thereby enhancing immune responses against cancer. This biosimilar provides researchers with a valuable tool for investigating TNFRSF9-mediated immune activation, studying T cell costimulation mechanisms, and exploring combination immunotherapy strategies in preclinical cancer models. It supports investigations into tumor immunology, immune checkpoint modulation, and cellular immune response enhancement.
Email: support@cusabio.com
Distributors Worldwide